- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.04. | Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why | 1 | Zacks | ||
| 02.04. | Gilead gains rights to Xilio's early-stage solid tumour candidate in deal worth up to $647.5m | 9 | PMLiVE | ||
| 02.04. | Xilio fires 21% of its workforce and reprioritises pipeline | 1 | Pharmaceutical Technology | ||
| 01.04. | Xilio Therapeutics reports Q4 results | 1 | Seeking Alpha | ||
| 01.04. | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 01.04. | Xilio Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 28.03. | Xilio and Gilead partner up for IL-12 therapeutic development | 6 | Pharmaceutical Technology | ||
| 28.03. | Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why | 3 | Benzinga.com | ||
| 28.03. | Gilead bets on Xilio cancer drug as biotech restructures | 8 | BioPharma Dive | ||
| 28.03. | Why Is Xilio Therapeutics (XLO) Stock up 168% Today? | 2 | InvestorPlace | ||
| 28.03. | HotStocks USA: +217 % bei Xilio | 3 | stock3.com | ||
| 28.03. | Xilio Prices Private Placement Of $11.3 Mln Of Shares, Updates XTX202 Trial; To Axe 21% Of Jobs | 5 | RTTNews | ||
| 28.03. | Xilio Therapeutics surges on license deal with Gilead, job cuts | 4 | Reuters | ||
| 28.03. | Xilio stock jumps on Gilead Sciences license deal | 4 | Seeking Alpha | ||
| 28.03. | Gilead pays $43.5M for early-phase IL-12 prospect from Xilio as biotech reduces head count | 7 | FierceBiotech | ||
| 28.03. | Xilio Therapeutics announces $11.3 million private placement equity financing | 4 | Seeking Alpha | ||
| 28.03. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.03. | Gilead, Xilio Announce Exclusive License Agreement For Tumor-Activated IL-12 Program XTX301 | 271 | AFX News | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Xilio Therapeutics, Inc. (XLO) announced an exclusive license agreement on Thursday to collaborate on Xilio's Phase 1 tumor-activated... ► Artikel lesen | |
| 28.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing | 3 | GlobeNewswire (USA) | ||
| 28.02. | Xilio Therapeutics, Inc.: Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,545 | -5,21 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,860 | +1,18 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,860 | +10,30 % | Looking Into Ginkgo Bioworks Holdings' Recent Short Interest | ||
| BEAM THERAPEUTICS | 21,360 | -1,11 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,010 | -1,94 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,120 | +3,57 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| ARCTURUS THERAPEUTICS | 26,550 | +1,45 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,828 | +5,49 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,790 | +1,74 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,730 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,230 | +7,86 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,140 | -1,29 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,350 | +3,21 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 2,680 | +1,71 % | Bio-Path files to sell 484K shares of common stock for holders | ||
| BIOMEA FUSION | 10,780 | +2,96 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
XILIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,090 Euro und damit +7,92 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
